Compare ATHM & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATHM | ZLAB |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | China | China |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2013 | 2017 |
| Metric | ATHM | ZLAB |
|---|---|---|
| Price | $22.74 | $18.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $28.00 | ★ $49.60 |
| AVG Volume (30 Days) | 656.0K | ★ 714.0K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.83% | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | $4.77 | $26.03 |
| P/E Ratio | $12.13 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $15.57 | $15.96 |
| 52 Week High | $29.92 | $39.64 |
| Indicator | ATHM | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 70.23 | 39.86 |
| Support Level | $21.78 | $16.84 |
| Resistance Level | $23.96 | $19.55 |
| Average True Range (ATR) | 0.78 | 0.76 |
| MACD | 0.10 | -0.25 |
| Stochastic Oscillator | 78.53 | 4.64 |
Founded in 2008 as a media content platform, Autohome is the leading online automobile platform in China, ranking first among automotive service platforms in terms of mobile daily active users, according to QuestMobile. Through its two websites, autohome.com.cn and che168.com, Autohome delivers comprehensive, independent, and interactive content and tools to automobile consumers as well as a full suite of services to automakers and dealers. According to iResearch, the company was the largest online automotive advertising and lead-generation service provider in China's online auto platform media advertising market, in terms of media services and lead-generation revenue.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.